Employees: 462
Size Kamada (KMDA) is a United States Health Care company (Biotechnology) with a market value of $465M, the 2725th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.07 on 18 Nov 2026.
Performance Over six months the shares gained 2.5%, against -8.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 19 in its peer set.
Growth Revenue grew 5.0% over the last twelve months (peer median -5.6%); the operating margin is 15.3% (peer median -17.2%).
Valuation It trades at 17.9× forward earnings against a peer median of 33.9× (3rd cheapest of 6).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.1 points above its cost of capital (9.6% WACC).
Short interest Short interest is 0.3% of the free float (30 Oct 2026).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $197M | $195M | $164M | $145M | $123M |
| Revenue growth | — | +19% | +13% | +17% | — |
| Gross profit | $81.8M | $78.3M | $67.1M | $52.6M | $41.2M |
| EBITDA | $45.7M | $44.5M | $34.4M | $24.1M | $16.8M |
| Net income | $24.7M | $21.9M | $14.7M | $8.41M | -$2.22M |
| Free cash flow | $35.7M | $16.9M | $37.4M | -$1.56M | $23.7M |
| Capital expenditure | $9.50M | $10.7M | $10.9M | $5.94M | $3.61M |
| Total debt | $11.7M | $11.6M | $11.1M | $8.75M | $20.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KMDA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.8% | -10.3% | 2nd highest of 21 |
| 6-month return | +2.5% | -8.0% | 8th highest of 19 |
| Distance from 52-week high | -13.7% | -41.1% | 2nd highest of 21 |
| Revenue growth (TTM) | +5.0% | -5.6% | 5th highest of 15 |
| Operating margin | 15.3% | -17.2% | highest of 15 |
| Forward P/E | 17.9× | 33.9× | 3rd cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | 5.0% | 18.6% | 2nd least demanding of 5 |
| Growth delivered (Del g) | +6.5% | +7.1% | 2nd lowest of 5 |
| Hurdle (Req g minus delivered) | -1.5 pp | +1.0 pp | 2nd least demanding of 5 |
| ROIC minus cost of capital | +2.1 pp | -11.3 pp | highest of 12 |
| EV / EBITDA | 8.8× | n/a | — |
| Net debt / EBITDA | -1.4× | -5.5× | 2nd most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 17.9× | 5.0% | +6.5% |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 2.3× | n/a | n/a |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 16.9× | 58.8% | +204.7% |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | n/a | n/a | n/a |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | n/a | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | n/a | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | n/a | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | n/a | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 37.5× | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | n/a | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | n/a | 29.4% | +7.0% |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 33.9× | 7.7% | +7.3% |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 39.4× | 2.1% | +0.5% |